Exelixis, Inc. ($EXEL) reported solid third-quarter 2026 results, with revenue rising to $658.7 million, up 10.2% from a year earlier. Gross profit increased to $632.5 million, while operating profit climbed to $268.4 million, reflecting continued profitability growth.
Net income attributable to common shareholders came in at $218.1 million, up 12.7% year over year, and diluted earnings per share rose to $0.85, a 23.2% increase. The company also generated $280.0 million in cash from operating activities during the quarter.
Performance was slightly ahead of expectations, with revenue just below the consensus estimate and earnings per share topping the forecast. Exelixis ended the period with $304.8 million in cash and cash equivalents, while total liabilities were $679.7 million.
- Revenue: $658.7 million
- Net income: $218.1 million
- Diluted EPS: $0.85
- Operating cash flow: $280.0 million
Note: This financials data is sourced from a third-party provider and has not been independently verified by Quiver.
Exelixis, Inc. Insider Trading Activity
Exelixis, Inc. insiders have traded $EXEL stock on the open market 6 times in the past 6 months. Of those trades, 0 have been purchases and 6 have been sales.
Here’s a breakdown of recent trading of $EXEL stock by insiders over the last 6 months:
- DANA AFTAB (EVP, Research and Development) sold 43,451 shares for an estimated $2,187,757
- CHRISTOPHER J. SENNER (EVP and CFO) sold 34,901 shares for an estimated $1,745,050
- MARY C BECKERLE sold 9,812 shares for an estimated $526,511
- SUE GAIL ECKHARDT sold 9,812 shares for an estimated $491,973
- BRENDA HEFTI (SVP and General Counsel) sold 6,625 shares for an estimated $332,641
- JACK L WYSZOMIERSKI sold 3,925 shares for an estimated $198,408
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
Exelixis, Inc. Hedge Fund Activity
We have seen 390 institutional investors add shares of Exelixis, Inc. stock to their portfolio, and 337 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- D. E. SHAW & CO., INC. added 3,691,742 shares (+198.5%) to their portfolio in Q2 2026, for an estimated $200,867,682
- SIXTH STREET PARTNERS MANAGEMENT COMPANY, L.P. added 2,261,816 shares (+inf%) to their portfolio in Q2 2026, for an estimated $123,065,408
- AQR CAPITAL MANAGEMENT LLC removed 2,071,798 shares (-15.8%) from their portfolio in Q2 2026, for an estimated $112,726,529
- TWO SIGMA INVESTMENTS, LP added 2,003,649 shares (+90.8%) to their portfolio in Q2 2026, for an estimated $109,018,542
- BLACKROCK, INC. removed 1,740,932 shares (-5.6%) from their portfolio in Q2 2026, for an estimated $94,724,110
- JPMORGAN CHASE & CO added 1,298,907 shares (+inf%) to their portfolio in Q2 2026, for an estimated $70,673,529
- FMR LLC removed 1,178,477 shares (-50.7%) from their portfolio in Q2 2026, for an estimated $64,120,933
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
Exelixis, Inc. Price Targets
Multiple analysts have issued price targets for $EXEL recently. We have seen 9 analysts offer price targets for $EXEL in the last 6 months, with a median target of $52.0.
Here are some recent targets:
- Gregory Renza from Truist Securities set a target price of $56.0 on 07/07/2026
- Leonid Timashev from RBC Capital set a target price of $46.0 on 07/07/2026
- Robert Burns from HC Wainwright & Co. set a target price of $56.0 on 07/02/2026
- Ashwani Verma from UBS set a target price of $52.0 on 07/02/2026
- Silvan Turkcan from Citizens set a target price of $55.0 on 06/24/2026
- Eva Fortea Verdejo from Wells Fargo set a target price of $40.0 on 05/06/2026
- Sean Laaman from Morgan Stanley set a target price of $50.0 on 05/06/2026
